AsianScientist (Apr. 22, 2013) – Chinese pharma Eddingpharm has entered into a collaboration agreement with GlaxoSmithKline China (GSK) to launch GSK’s drug for advanced or metastatic breast cancer in China.
Tykerb (USAN: lapatinib ditosylate, trade name: lapatinib) is a small molecular reversible inhibitor of tyrosine kinase (TKI) with effective absorption upon oral administration. To date, Tykerb has been approved for the same indication in more than 100 countries.
Lapatinib was recently approved for clinical use in China by the State Food and Drug Administration (SFDA). It is used in combination with capecitabine for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress HER2 and who have received prior therapy with an anthracycline, a taxane and trastuzumab.
“This cooperation with GSK on Tykerb is not only a milestone of Eddingpharm’s business development history, but also an important milestone of China’s pharmaceutical industry. This is the first time a Chinese pharmaceutical company will participate in the launch of a proprietary global oncology drug,” said Mr. Xin Ni, Chairman and CEO of Eddingpharm.
Breast cancer has become the most commonly diagnosed cancer among Chinese women, with approximately 170,000 new cases diagnosed each year.
——
Source: Eddingpharm.
Disclaimer: This article does not necessarily reflect the views of AsianScientist or its staff.
